CoLucid Pharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | |
|---|---|---|
| Revenue | — | — |
| Operating income | −$30.9M | −$2.3M |
| Net income | −$30.7M | −$3.0M |
| Total assets | $65.3M | $293,253 |
| Total liabilities | $6.9M | $2.1M |
| Equity | $58.4M | −$1.8M |
| EPS (diluted) | — | — |
| Shares out. | 15.3M | 143,810 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- —
- Net margin
- —
- Return on equity
- −52.6%
- Return on assets
- −47.0%
- Return on capital (ROCE)
- −51.5%
- Liabilities / assets
- 10.6%
- Debt / equity
- 0.12×
- Book value / share
- $3.82
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Altman Z″ (distress)
- 7.34safe
- Accruals / assets
- −13.8%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Lilly Eli &Amp; Co10% owner | Mar 1, 2017 | J | 19.3M | $46.50 |
| Pappas Arthur MDirector | Mar 1, 2017 | U | 1.9M | $46.50 |
| Skwierczynski RaymondOfficer — Head,Pharmaceutical Operations | Mar 1, 2017 | U | 3,615 | $46.50 |
| Mathers Thomas P.Officer — Chief Executive Officer | Mar 1, 2017 | U | 173,519 | $46.50 |
| Marengere LucDirector | Mar 1, 2017 | U | 1.5M | $46.50 |
| Kuca BerniceOfficer — Head,Clin. and Reg. Operations | Mar 1, 2017 | U | 2,729 | $46.50 |
| Dallas Matthew DOfficer — Chief Financial Officer | Mar 1, 2017 | U | 2,708 | $46.50 |
| Mathers Thomas P.Officer — Chief Executive Officer | Jan 5, 2017 | Option exercise | 3,755 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 1, 2017
- Entered a material agreement · Director / officer change · Other material eventJan 18, 2017
- Results of operationsNov 9, 2016
- Director / officer changeOct 12, 2016
- Regulation FD disclosure · Other material eventSep 9, 2016
- Other material eventSep 8, 2016
- Results of operationsAug 10, 2016
- Results of operationsMay 11, 2016
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13D/AApr 20, 2017
- 15-12BMar 13, 2017
- EFFECTMar 3, 2017
- S-8 POSPOST EFFECTIVE AMEND NO 1 TO FORM S-8Mar 2, 2017
- S-8 POSPOST EFFECTIVE AMEND NO 1 TO FORM S-8Mar 2, 2017
- POS AMMar 2, 2017
- SC 13D/AMar 2, 2017
- 4FORM 4 SUBMISSIONMar 1, 2017
- SC 13D/AMar 1, 2017
- 8-KMar 1, 2017
- 4PRIMARY DOCUMENTMar 1, 2017
- 4PRIMARY DOCUMENTMar 1, 2017
- 4PRIMARY DOCUMENTMar 1, 2017
- 4PRIMARY DOCUMENTMar 1, 2017
- 4PRIMARY DOCUMENTMar 1, 2017
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.